Evidence map›Paper›PMID 40839636›Full record

ArticlePloS one2025

A lightweight cross-scale feature fusion model based on YOLOv8 for defect detection in sewer pipeline.

Ruibo Sha, Zhifeng Zhang, Xiao Cui, Qingzheng Mu

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruibo ShaSoftware Engineering College, Zhengzhou University of Light Industry, Zhengzhou, Henan, China.ORCID https://orcid.org/0009-0005-5668-4952
Zhifeng ZhangSoftware Engineering College, Zhengzhou University of Light Industry, Zhengzhou, Henan, China.ORCID https://orcid.org/0000-0002-2303-9800
Xiao CuiSoftware Engineering College, Zhengzhou University of Light Industry, Zhengzhou, Henan, China.
Qingzheng MuSoftware Engineering College, Zhengzhou University of Light Industry, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sewer pipeline defect detection is a critical task for ensuring the normal operation of urban infrastructure. However, the sewer environment often presents challenges such as multi-scale defects, complex backgrounds, lighting changes, and diverse defect morphologies. To address these issues, this paper proposes a lightweight cross-scale feature fusion model based on YOLOv8. First, the C2f module in the backbone network is replaced with the C2f-FAM module to enhance multi-scale feature extraction capabilities. Second, the HS-BiFPN module is adopted to replace the original structure, leveraging cross-layer semantic fusion and feature re-weighting mechanisms to improve the model's ability to distinguish complex backgrounds and diverse defect morphologies. Finally, DySample is introduced to replace traditional sampling operations, enhancing the model's ability to capture details in complex environments. This study uses the Sewer-ML dataset to train and evaluate the model, selecting 1,158 images containing six types of typical defects (CK, PL, SG, SL, TL, ZW), and expanding the dataset to 1,952 images through data augmentation. Experimental results show that compared to the YOLOv8n model, the improved model achieves a 3.8% increase in mAP, while reducing the number of parameters by 35%, floating-point operations by 21%, and model size by 33%. By improving detection accuracy while achieving model lightweighting, the model demonstrates potential for application in pipeline defect detection.

Indexed as

Models, TheoreticalSewageAlgorithmsSewage

Identifiers

PMID40839636
PMCPMC12370142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.